HAVCR2 and neoplasm: Immune checkpoints such as Programmed Cell Death Protein 1 (PD-1), T cell immunoglobulin domain and mucin domain-3 (TIM-3), and Lymphocyte activation gene-3 (LAG-3), which are often activated in the tumor tissue and regulate T-cell function, are important immunotherapy targets (26–28).